Overview

Study of Probuphine in Patients With Opioid Dependence

Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Titan Pharmaceuticals
Treatments:
Analgesics, Opioid
Buprenorphine